Carglumic Acid Market Projected to Reach US $190 Mn by 2026
Carglumic acid is an orphan drug that is utilized for treatment of patients with hyperammonemia, which implies deficiency of N-acetylglutamate (NAG) synthase. Well known as N-carbamoyl-L-glutamic acid (NCGA) or Carbaglu, carglumic acid stimulates the initial enzyme in urea cycle, which helps in detoxification and removal of ammonia from blood cells. Carglumic acid is on the verge of becoming an indispensable therapeutic tool for managing life-threating & rare inborn metabolic disorders that affect the urea cycle.
View full press release